Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue Depreciation & Amortization (IS)EBIAT Gross Profit Leases Long-Term Debt Issuances Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

Insight Molecular Diagnostics (IMDX) Long-Term Debt Repayments (2016 - 2022)

Insight Molecular Diagnostics' Long-Term Debt Repayments history spans 3 years, with the latest figure at $575000.0 for Q3 2022.

On a quarterly basis, Long-Term Debt Repayments rose 53.33% to $575000.0 in Q3 2022 year-over-year; TTM through Dec 2022 was $1.3 million, a 11.67% decrease, with the full-year FY2022 number at $1.3 million, down 11.67% from a year prior.
Long-Term Debt Repayments hit $575000.0 in Q3 2022 for Insight Molecular Diagnostics, up from $375000.0 in the prior quarter.
Over the last five years, Long-Term Debt Repayments for IMDX hit a ceiling of $575000.0 in Q3 2022 and a floor of $250000.0 in Q4 2020.
Historically, Long-Term Debt Repayments has averaged $384375.0 across 3 years, with a median of $375000.0 in 2021.
The widest YoY moves for Long-Term Debt Repayments: up 53.33% in 2022, down 0.0% in 2022.
Tracing IMDX's Long-Term Debt Repayments over 3 years: stood at $250000.0 in 2020, then soared by 50.0% to $375000.0 in 2021, then skyrocketed by 53.33% to $575000.0 in 2022.
Business Quant data shows Long-Term Debt Repayments for IMDX at $575000.0 in Q3 2022, $375000.0 in Q2 2022, and $375000.0 in Q1 2022.